# 日本衛材（4523.T）將授權上海復星醫藥（2696.HK）的肺癌藥物漢思莊。

*biotech · news · 2026-02-05 · Reuters*

## Key points

- 衛材將授權復星醫藥的肺癌藥物漢思莊，並支付7500萬美元的前期款項。
- 根據此協議，復星醫藥可從衛材獲得最高3.1334億美元的里程碑付款。
- 衛材的授權涵蓋漢思莊在日本作為注射劑的開發、生產及商業化。
- 復星醫藥已與多個業務夥伴合作，在超過100個國家和地區推廣漢思莊。

SHANGHAI, Feb 5 (Reuters) - Japan's Eisai (4523.T), opens new tab will licence Shanghai Henlius Biotech's (2696.HK), opens new tab lung cancer drug Hansizhuang, paying $75 million upfront and up to $313.34 million more if milestones are met, the Chinese drugmaker said on Thursday. The deal is the latest overseas licensing agreement for the drug, approved in markets including China and the European Union, which for Henlius brought in sales, opens new tab of .6 billion yuan in the first half of 2025. Sign up here. Henlius has entered into business partnerships for commercialising Hansizhuang in more than 100 countries and regions, it said in a filing, opens new tab. Under the agreement with Eisai, it is eligible to receive up to $80.01 million in payments tied to regulatory milestones, and up to $233.33 million for sales-related milestones, plus additional royalties based on annual net sales. The agreement covers the development, manufacturing and commercialisation of the drug as an injection. Eisai has been granted a license in Japan for oncology indications. Reporting by Andrew Silver in Shanghai, Editing by Louise Heavens

**Companies:** Eisai, Shanghai Henlius Biotech
**Countries:** Japan, China

[Read the full story on Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/eisai-strikes-japan-licensing-deal-with-shanghai-henlius-biotech-2026-02-05/)

---

Canonical: https://newsio.io/zh-TW/n/f7f2daef-2b28-4bf1-afa6-063c30feffd7/4523-t2696-hk
Summarized by Newsio from Reuters. https://newsio.io/how-it-works